Zydus’ ZYCUBO May Be the Proof Point the Industry Needed For decades, Indian pharma has won by playing the volume game—generics, cost arbitrage, regulatory stamina, scale. That model built giants. It also hit a ceiling. On January 11, 2026, Zydus Lifesciences quietly signalled what the next growth chapter could look like. Through its US arm…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
